6 May 2025
AusBiotech's Medtech Invest 2025, Australia's premier medical technology investment conference, opens today in Sydney — kicking off a landmark week fostering meaningful connections, advancing collaboration, and driving growth in devices and diagnostics.
Medtech Invest sets the stage for the country's biggest week in medtech, with the main AusMedtech 2025 conference launching tomorrow, Wednesday 7 May.
Against a backdrop of a rapidly evolving global landscape marked by geopolitical and trade shifts, supply chain challenges, ageing populations, chronic disease and more, Medtech Invest 2025 brings together sector leaders to advance breakthroughs, connect capital with opportunity, and empower the medtech sector to deliver real-world health solutions.
Rebekah Cassidy, CEO of AusBiotech, said the investor-focused event will help accelerate the delivery of real-world, home growth, health solutions.
"With over 900 medtech companies operating in Australia, it's clear the sector is thriving — but growth doesn't happen without capital and investment. We're proud to build on our strong legacy and commitment to investment, to connect innovators with the capital and connections they need to scale and succeed."
Today's program offers a deep dive into the evolving medtech investment landscape — exploring capital flows, global market trends, and the critical role of intellectual property in driving investor confidence.
The conference brings together a diverse delegation of Australian and international investors, medtech companies, venture capitalists, private equity leaders, brokers, analysts, executives, and global thought leaders.
Medtech program
The half-day event features leading voices in medtech investment, including Dr Nicholas Pachuda from Peptilogics, Neovate Capital and Precision Life Science Partners, who brings global expertise in scaling breakthrough technologies. Kylie Frazer of Flying Fox Ventures will offer sharp insights into early-stage investment, while Elyse Shapiro of Canaccord Genuity will provide valuable market intelligence across biotechnology and diagnostics.
Medtech Invest will also feature a panel session exploring innovation, IP and commercialisation, with Gorjana Mitic, Business Development and Licensing Manager at Children's Cancer Institute, chairing the discussion. She will be joined by Helen Mutimer, Head of IP Advisory at FB Rice; Dr Simon Puttick, Chief Scientific Officer at Advancell; and Prashanth Rajan, Associate at Brandon Capital.
A total of 11 private and ASX-listed medtech companies will present throughout the day, including ten early- to late-stage ventures delivering focused ten-minute pitch presentations. Investors will gain a view of emerging opportunities across diagnostics and devices. Presenting companies include: Convergence, CYBAN, EM Vision (ASX:EMV), Examin Holdings, Gelomics, Haemograph, HiFi-Ortho, Integrant, Kardiomics, Navi, and Venstra Medical. Read the full investee list here.
"AusBiotech's Invest event portfolio is another example of how we work to foster home grown medical innovation capability that's good for the future health and wealth of our nation. Our investment events are about supporting innovators, forging partnerships that support commercial success," says Rebekah.
"We are proud to champion Australia's medtech ingenuity and ensure it gains the attention and investment it deserves."
Medtech Invest builds on the success of AusBiotech Invest a flagship investment event, and its well-established investment attraction programme that for almost 16 years has helped empower Australian companies to be competitive on a global scale, while connecting Australian life sciences companies with international capital markets, and risk-tolerant investors with investment-seeking life science companies.
Medtech Invest signals the start of an exciting week in medtech, with AusMedtech 2025, Australia's leading medtech conference, running in Melbourne from 7–8 May 2025.
For full program details and speaker information, visit: www.ausmedtech.com.au
